Dr. Cora Sternberg: Developments in the Treatment of Castration-Resistant Prostate Cancer

(00:08:35) EJC News Focus, 2011 Apr 1

In this edition of EJC News Focus, Helen Saul discusses exciting developments in the treatment of castration-resistant prostate cancer with EJC’s editor for genitourinary cancers, Cora Sternberg (San Camillo and Forlanini Hospitals, Rome, Italy).

See related videos to:
EJC News Focus

Related Links:

Improved survival outcomes in clinically relevant patient subgroups from COU-AA-301, a phase III study of abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer progressing after docetaxel-based chemotherapy. Presented at ASCO GU, 2011 by Howard Scher, Abstract #4. »
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Johann Sebastian de Bono et al, Lancet 2010; 376: 1147-54 »
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Karim Fizazi et al, Lancet 2011; 377: 813-822 »
Sipuleucel-T immunotherapy for castration-resistant prostate cancer. Philip Kantoff et al, N Engl J Med 2010; 363: 411-422 »